FYR Bio

The catalyst to innovate diagnostics and transform healthcare.

[FYR Bio @FYR_Bio]

What development decision will your biomarker data inform? Define that first, then choose the samples and measurements. FYR Bio works with pharma and biotech teams on blood-based EV RNA/protein analysis.

#Biomarkers

[FYR Bio @FYR_Bio]

Tumor SPARCs use affinity-based capture to enrich tumor-associated extracellular vesicles from blood while preserving intact vesicles for RNA and protein analysis. Learn more about FYR Bio's approach: https://t.co/hyeWpiYtnj

#Oncology

[FYR Bio @FYR_Bio]

Meet FYR Bio at MJFF’s Parkinson’s Disease Therapeutics Conference, Oct. 14–15 in NYC.

Discuss how EVO and Neuro SPARCs can help you study disease mechanisms, measure drug effects, and explore treatment response.

Schedule time: [email protected]

#ParkinsonsDisease

[FYR Bio @FYR_Bio]

FYR Bio's Neuro SPARCs are designed to enrich brain-associated extracellular vesicles from blood for RNA and protein analysis, supporting biomarker research in neurological drug development.

#Neurodegeneration #Biomarkers

[FYR Bio @FYR_Bio]

People power our progress.

Congratulations to Rachel, FYR’s Employee of the Quarter, recognized for Connection. Rachel strengthens communication across FYR and helps cross-functional work move forward with clarity and focus.

Thank you, Rachel.

#Biotech #Team #EmployeeSpotlight

[FYR Bio @FYR_Bio]

BIO 2026 is underway in San Diego.

FYR Bio CEO Dr. Chris Booth is attending this week to connect with biotech and pharma partners advancing biomarker-driven drug development and smarter trials.

Connect through BIO Partnering or email [email protected].

#BIO2026 #DrugDevelopment

[FYR Bio @FYR_Bio]

Next week, FYR Bio CEO Dr. Chris Booth will be in San Diego to connect with biotech and pharma partners focused on better biomarkers, smarter trials, and precision medicine.

Attending BIO? Connect through BIO Partnering or email [email protected].

#BIO2026 #Biomarkers

[FYR Bio @FYR_Bio]

We’re at ASCO!

FYR Bio is meeting with teams across oncology drug development to discuss how Tumor SPARCs can support biomarker discovery, patient stratification, and longitudinal monitoring.

Email [email protected] to schedule time.

[FYR Bio @FYR_Bio]

Heading to ASCO next week? Meet the FYR Bio team.

We’re looking forward to conversations on oncology drug development and how Tumor SPARCs can support biomarker discovery, patient stratification, and pharmacodynamic studies.

Email [email protected] to connect.

[FYR Bio @FYR_Bio]

Unlock tumor-derived signals with Tumor SPARCs™.

FYR Bio’s TumorSPARCs™ captures tumor-derived EV subpopulations from blood and preserves intact vesicles for downstream multiomic analysis in oncology drug development.

More:
https://t.co/c6tbGDXPXe

#Oncology #DrugDevelopment

[FYR Bio @FYR_Bio]

We’re at AACR 2026 this week.

FYR Bio is on-site to connect with teams advancing oncology drug development. Our EV-Omics platform supports stronger biomarker discovery and translational insight from blood-based signals.

Email [email protected] to meet. #AACR2026 #Oncology

[FYR Bio @FYR_Bio]

Heading to AACR 2026 next week? Meet the FYR Bio team.

We’re looking forward to conversations on oncology drug development and how our EV-Omics platform can support biomarker discovery and translational research.

Email [email protected] to connect. #AACR2026 #Oncology

[FYR Bio @FYR_Bio]

Our platform drives real-world impact across #ClinicalDevelopment: early & accurate detection, treatment monitoring, patient stratification, and risk assessment.
We make #PrecisionMedicine actionable.
More: https://t.co/o69ZrVmvc5

#NeuroDiagnostics #Biomarkers

[FYR Bio @FYR_Bio]

Advancing precision medicine isn’t just about data; it’s about making data actionable. We empower researchers to ask better questions and get better answers by delivering biologically relevant insights from blood-based signals.

Meet with us:

https://t.co/OBiDLP3Vrl

[FYR Bio @FYR_Bio]

February is #CancerPreventionMonth, a time to recognize the importance of awareness, prevention, early detection, and continued progress against #Cancer.

We’re focused on generating clearer molecular insight from blood-based signals to support more informed research.

[FYR Bio @FYR_Bio]

FYR appoints @BKZehentner as COO.
She brings > 25 years of experience in precision medicine and operational leadership. She joins as we scale our EVO platform to unravel the complexity of disease mechanisms.

Learn more: https://t.co/GDlDrwxJFJ

[FYR Bio @FYR_Bio]

Today on #WorldCancerDay, we honor the patients, caregivers, and scientists working to improve #Cancer outcomes.

At FYR, we’re advancing precision medicine with our AI-enabled EV-Omics platform to support better biomarkers, smarter trials, and more informed research.

#Oncology

[FYR Bio @FYR_Bio]

Live from the 14th #Alzheimers & #Parkinsons Drug Development Summit!

Make sure you stop by our booth (#11) to learn more about our work and connect with the FYR team!

[FYR Bio @FYR_Bio]

Next week, we’ll be in Boston for the #Alzheimer’s & #Parkinson’s Drug Development Summit!

Stop by our booth (#11) w/ @HerantisPharma to learn more about our work or book a meeting with the FYR team:  https://t.co/OBiDLP3Vrl

[FYR Bio @FYR_Bio]

FYR accelerates #Neurology R&D with our #AI-powered EV-Omics platform, translating EV protein & RNA data into insights that power #Biomarker discovery, patient stratification & smarter trial design, turning #Molecular data into precision for pharma.

More https://t.co/WEMzRFKxVK